New era of dialysis: expanded haemodialysis (HDx)
Journal Title: Нирки - Year 2019, Vol 8, Issue 1
Abstract
The article is addressed to practical physicians involved in renal replacement therapy, mainly haemodialysis (HD). The article presents a new method for haemodialysis — expanded haemodialysis, assesses its efficiency, and is focused on the problem of large medium molecules elimination. The essence of the method is to use the THERANOVA haemodialyser with the usual infrastructure. The term expanded HD (HDx) has been proposed to determine a method where diffusion and convection are conveniently combined in THERANOVA dialysis with a hollow fibre and equipped with a membrane for middle cut-off. A standard dialysis device can easily perform this technique without special software or additional sophisticated technology. To achieve optimal clearance in the system blood flow 300 ml/min and dialysate flow ≥ 500 ml/min is sufficient. In HDx, the convection flow is supported by internal filtering, but it is offset by the reverse filtering mechanism inside the filter. The special configuration of the membrane with reduced inner diameter provides high convection rates thanks to the combined pre- and post-dilution configuration. Thus, the use of THERANOVA gives to the haemodialysis capabilities of haemodiafiltration. However, the THERANOVA dialyser should not be used for haemodiafiltration in a reason of a potential enlarging of albumin removal. Expanded haemodialysis is advisable to be used in patients with complications associated with the effects of uremic toxins. Expanded haemodialysis may be a rational therapy for patients who are moving from peritoneal dialysis to HD while waiting for transplantation, which is an example of an individualized, personified approach.
Authors and Affiliations
D. D. Ivanov
Keywords
Related Articles
- EP ID EP474034
- DOI 10.22141/2307-1257.8.1.2019.157797
- Views 90
- Downloads 0
Clinical case of successful treatment of Goodpasture syndrome with rituximab
.
Nifuratel Application in Therapy of Urinary Tract Infections
Increased multidrug resistance of extended-spectrum beta-lactamases (ESBLs) compromises the efficacy of treatment of urinary tract infections. The objective of this study is to determine the prevalence of ESBL-producing...
Next Step in Chronic Kidney Disease Therapy
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the ac...
The role of levocarnitine in the systemic therapy of patients of different profile of patients on chronic hemodialysis
the paper presents the pharmacological characteristics of L-carnitine and evaluation of the effectiveness of its application in nephrology practice. Discussed the evidence of the use of levocarnitine for chronic kidney d...
Active Follow-up in Patients with Localized Prostate Cancer: Evaluation of Long-term Results
Among the clinical recommendations one of the standard approaches in the treatment of prostate cancer is active follow-up. For 13 years, under the supervision there were 85.7 % of patients. Overall 3-, 5- and 7-year surv...